Abstract

Coronavirus disease 2019 (COVID-19) is highly contagious and has affected the whole world. We seek to investigate the clinical and laboratory characteristics of COVID-19 patients in the high altitude areas of Sichuan, China. In this retrospective cohort study, a total of 67 patients with laboratory-confirmed SARS-CoV-2 infections in Sichuan's Ngawa Tibetan and Qiang Autonomous Prefecture were included from February 1, 2020, to March 2, 2020. Their clinical characteristics, as well as radiological and laboratory features, were extracted. Four (6.0%) patients were categorized as severe cases; 39 (58.2%) were non-severe cases, and 24 (35.8%) were asymptomatic cases. A total of 46 (68.7%) patients were associated with cluster infection events in this study. The most common symptoms were cough, sputum production, dyspnea, fatigue or myalgia, and headache. Seven (10.4%) patients showed leucopenia, and 20 (29.9%) patients showed lymphopenia. Lymphocyte counts and neutrophil-to-lymphocyte ratios (NPR) were different between the three groups. In total, 14 (20.9%) patients had thrombocytopenia, and prothrombin times (PT) and fibrinogen levels differed between groups. We also found significant differences in sodium, chloride and calcium levels between the three groups. Antiviral therapy did not lead to obvious adverse events or shortened durations from initial positive to subsequent negative nuclei acid tests. Advanced age, hypertension, high neutrophil count, the neutrophil-to-lymphocyte ratio, fibrinogen and lactate dehydrogenase levels were identified as independent risk factors for symptomatic cases of COVID-19. In conclusion, the symptoms of patients in high altitude areas were mild, and about one third were asymptomatic. We also identified several independent risk factors for symptomatic cases of COVID-19.

Highlights

  • In December 2019, a case of pneumonia of unknown cause was detected in Wuhan, Hubei province, China [1]

  • A total of 46 (68.7%) patients were associated with cluster infection events in this study

  • A total of 67 patients from Sichuan’s Ngawa Tibetan and Qiang Autonomous Prefecture in China confirmed as COVID-19 positive were included in this study, with four (6.0%) patients categorized as severe cases, 39 (58.2%) patients categorized as non-severe cases and 24 (35.8%) patients categorized as asymptomatic cases on admission

Read more

Summary

Introduction

In December 2019, a case of pneumonia of unknown cause was detected in Wuhan, Hubei province, China [1]. The pathogen was quickly revealed as a novel betacoronavirus named the “2019 novel coronavirus” (2019-nCoV), which was subsequently renamed as the “Severe Acute Respiratory Syndrome Coronavirus 2” (SARS-Cov-2). The virus is the seventh member of the coronavirus family and belongs to the betacoronavirus 2B lineage, sharing a genome that is 96% identical with BatCov RaTG13, a SARS-like coronavirus in bats [2]. The outbreak of the disease was declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO) on January 30, 2020 [3]. The WHO named it “coronavirus disease 2019” (COVID-19) on February 11, 2020 [3]. COVID-19 is highly contagious and has rapidly impacted the entire world, affecting more than 200 countries and territories

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call